KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Assets Average (2016 - 2025)

Historic Assets Average for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to $2.1 billion.

  • CRISPR Therapeutics AG's Assets Average fell 698.36% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year decrease of 698.36%. This contributed to the annual value of $2.2 billion for FY2024, which is 2.29% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Assets Average of $2.1 billion as of Q3 2025, which was down 698.36% from $2.1 billion recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Assets Average peaked at $2.9 billion during Q3 2021, and registered a low of $1.9 billion during Q1 2021.
  • Moreover, its 5-year median value for Assets Average was $2.3 billion (2024), whereas its average is $2.3 billion.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Assets Average skyrocketed by 13650.57% in 2021, and later crashed by 1753.25% in 2022.
  • CRISPR Therapeutics AG's Assets Average (Quarter) stood at $2.8 billion in 2021, then decreased by 17.53% to $2.3 billion in 2022, then fell by 6.09% to $2.2 billion in 2023, then rose by 4.21% to $2.2 billion in 2024, then decreased by 4.96% to $2.1 billion in 2025.
  • Its Assets Average was $2.1 billion in Q3 2025, compared to $2.1 billion in Q2 2025 and $2.2 billion in Q1 2025.